Company Profile

Curtana Pharmaceuticals Inc
Profile last edited on: 5/17/18      CAGE: 6WCS9      UEI: PM1PJ3RUXZ54

Business Identifier: small molecule therapeutics highly specific for CNS, focusing on treatment of glioblastoma (GBM) and other brain cancers.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1624 Headway Circle Suite 100
Austin , TX 78754
   (512) 900-3696
Location: Multiple
Congr. District: 10
County: Travis

Public Profile

Based in Austin, TX but with facilities also in California, Curtana Pharmaceuticals is a biopharmaceutical company developing small molecule therapeutics. These therapeutics are specifically designed to target cancer stem cells in the central nervous systems (CNS) that can be used to treat various forms of brain cancer. Curtana's focus thus far has been on the treatment of glioblastoma (GBM), the most common and deadly form of brain tumor found in adults. Curtana’s OLIG2 inhibitor proteins may also be effective in treating melanoma and pre-T-cell leukemia as well as some small cell lung cancers and breast cancers. The company was founded on the research of Dr. Santosh Kesari at the University of California San Diego School of Medicine's Moores Cancer Center

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 1 NIH $300,000
Project Title: Discovery of Novel Therapeutics for Glioblastoma
2014 1 NIH $225,000
Project Title: Validation of a Novel Treatment for Glioblastoma

Key People / Management

  Gordon Alton

  Santosh Kesari

  Sandeep C Pingle